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Abstract 
Background: Chronic infection with the hepatitis B virus and obesity may both contribute synergistically to liver disease, although rela-
tively few studies have investigated this hypothesis. Therefore, in this study, we evaluated the relationship between central obesity and the 
liver stiffness in the Golestan Hepatitis B cohort study (GHBCS). 
Methods: Our study included 304 chronic hepatitis B (CHB) patients enrolled from GHBCS. Liver stiffness measurement (LSM) and labo-
ratory tests were performed after a follow-up of 4 years (2012). The hepatitis B viral load was measured at the baseline and follow-up using 
WKHUHDOWLPH3&5PHWKRG:DLVWFLUFXPIHUHQFHFPLQPHQDQGFPLQZRPHQFHQWUDOREHVLW\ZDVFRQVLGHUHGWREHDEQRUPDO
$GYDQFHGOLYHUVWLIIQHVV$/6ZDVGH¿QHGDV/60.3D6WDWLVWLFDODQDO\VLVZDVSHUIRUPHGXVLQJ63669/RJLVWLFUHJUHVVLRQZDV
XVHGWRWHVWSUHGLFWRUVRIDGYDQFHGOLYHUVWLIIQHVV/60.3D/LQHDUUHJUHVVLRQZDVXVHGWRWHVWWKHSUHGLFWLYHYDOXHRIYDULDEOHVLQ$/7
(as a continuous variable). P-YDOXHRIOHVVWKDQZDVFRQVLGHUHGVWDWLVWLFDOO\VLJQL¿FDQW 
Results:$PRQJWKHVH&+%SDWLHQWVFDVHVZLWKDPHDQ6'DJHRIGHYHORSHG$/6DIWHU\HDUVRIIROORZXS 
0XOWLYDULDWHDQDO\VLVVKRZHGDVLJQL¿FDQWSUHGLFWLYHUROHRIFHQWUDOREHVLW\DQGYLUDOORDGLQ$/6 
Conclusions: Central obesity is related to the liver stiffness in chronic hepatitis B patients. 
Keywords: Central obesity, chronic Hepatitis B, liver fibrosis, liver stiffness, waist circumference 
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Introduction 
M ore than 350 million individuals are chronically infectedwith the Hepatitis B virus (HBV) worldwide. A propor­
tion of these individuals develop progressive liver dis­
eases,1 so it is critical to identify the determinants of disease pro­
gression in order to develop preventive approaches.2  
Published data have shown a prominent role of metabolic factor
in the natural course of HBV along with the viral factors.3–5 Fur­
thermore, the key metabolic genes are regulated similar in HBV
infected hepatocytes and in patients with metabolic disorders. It
has been shown that hypertriglyceridemia, central obesity and
diabetes mellitus could lead to hepatocyte damage through oxi­
dative stress and fat accumulation (steatosis).3,6 Although, there
would be a relationship between metabolic factors and HBV. As
HBV viral load has been reported to be lower in obese patients
(HBeAg seropositive carriers) and those with hypertriglyceride­
mia (HBeAg seronegative carriers).6 
The incidence of obesity and type 2 diabetes are increasing in
developing countries due to the industrial lifestyle. In addition,
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obesity plays role in hepatocelular carcinoma (HCC)3,4,6 so it
seems certain that the number of patients having both chronic
hepatitis B (CHB) and obesity is increasing too.3,4 There are far
less data available about the interrelationship of metabolic factors
and HBV comparing to hepatitis C.3,7 
Metabolic risk factors are concomitant with increased visceral
fat.8$GLSRVH WLVVXH GLVWULEXWLRQ LQÀXHQFHV PHWDEROLF FRPSOLFD­
tions. Visceral adiposity is a better predictor of fatty liver than
body mass.8–10 Those with visceral fat adiposity appear to be at
greater risk for fatty liver, due to their ability for transporting free
fatty acids directly into the portal vein for conversion to triglyc­
erides. Abdominal fat is thought to be associated with both liver
steatosis and further consequences such as insulin resistance,9 as
it has been proposed a key indicator of fat deposition in hepato­
cytes.11 
The exact role of fat accumulation and distribution through the
ERG\LQWKHQDWXUDOKLVWRU\RI&+%UHPDLQVWREHFODUL¿HGLQORQ­
gitudinal studies. However, such studies are scarce. Here, we fol­
lowed a cohort of naïve patients with chronic hepatitis B to evalu­
ate the relationship between central obesity and the liver stiffness. 
Materials and Methods 
Study population 
Out of 3505 participants of Golestan Hepatitis B cohort study
*ROHVWDQ +%&6  WUHDWPHQWQDwYH &+% SDWLHQWV GH¿QHG 
as being HBsAg positive and HBeAg negative, were randomly
selected according to current guidelines.12,13 The treatment-naïve
&+%SDWLHQWVGLGQRWKDYHFRLQIHFWLRQZLWKKXPDQLPPXQHGH¿­
ciency virus (HIV), hepatitis C virus, hepatitis D virus, hepatitis G
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virus; autoimmune hepatitis; alcohol consumption; recent blood The HBV DNA level was assessed both qualitatively and quanti­
transfusion; pregnancy; and hemochromatosis. tatively, at baseline and follow up steps. 
Anthropometric data, including body weight, height, and waist
6WDWLVWLFDODQDO\VLVcircumference, were measured according to standardized proce­
dures. Body mass index (BMI) was calculated by dividing weight Statistical analysis was performed using SPSS-V17. Data were
(kg) to height (m2). Waist circumference (WC) was measured at expressed as mean ± SD and number (percent) for continues and
the midpoint between the superior aspect of the iliac crests and the categorical data, respectively. Chi-square test and t-tests were
lower lateral margins of the ribs using an inelastic tape (TBW Im­
port Ltd) that was 0.5 cm in width and 200 cm in length, accord­
ing to World Health Organization (WHO) recommendations.14 
&HQWUDOREHVLW\ZDVGH¿QHGDVKDYLQJDQDEQRUPDOZDLVWFLUFXP­
IHUHQFHEDVHGRQWKHXSGDWHGGH¿QLWLRQRI0HWDEROLF6\QGURPH
in the National Cholesterol Education Program Adult Treatment
Panel III (NCEPAT III) criteria: waist circumference > 102 cm in
PHQRU!FPLQZRPHQDQGEORRGSUHVVXUHPP+JRU
current use of antihypertensive medications have been considered
abnormal.15 
Blood samples were collected and assessed for complete blood
count including: platelet, liver and kidney function tests, as well
DVEORRGFKHPLVWU\LQFOXGLQJOLSLGSUR¿OHV:ULWWHQLQIRUPHGFRQ­
sent was obtained from all individuals. Study was conducted ac­
cording to the Declaration of Helsinki. This study was approved
by the Institutional Review Board and the Ethics Committee of
Digestive Disease Research Institute (DDRI), Tehran University
of Medical Sciences. 
Study design 
$W WKH¿UVWYLVLWGHPRJUDSKLFGDWDZDV UHFRUGHGDQG+%V$J
was assessed. After 4 years, liver stiffness was assessed by tran­
sient elastography; and 10 mL of peripheral venous blood was
collected. Serum and plasma were stored at -70°C until further
processing. 
Liver Stiffness Measurement (LSM) 
Liver stiffness was measured by a trained medical doctor us­
ing the FibroScan® 502 machine (EchoSense, Paris, France, 5
used. Those variables with a P-value < 0.2 or biological plausi­
bility in the univariate analysis were included in the multivariate
analysis. Logistic regression was used to test predictors of ad­
YDQFHGOLYHUVWLIIQHVV/60.3DDQG$/7DVDFRQWLQXRXV
variable). P-value of less than 0.05 was considered statistically
VLJQL¿FDQW
Results 
3DWLHQWV¶ EDVHOLQH FKDUDFWHULVWLFV DQG SUHYDOHQFH RI DEGRPLQDO
obesity 
Overall, 304 treatment-naïve CHB patients were studied. Mean
age (±SD) was 52 (±8.13) years and 149 (49%) were male. All
patients were urban residents. At baseline, 142 (46.7%) had high
blood pressure. The mean (±SD) BMI was 28.5 ± 5.3 kg/m2. Ab­
dominal obesity was seen in 101 (68%) of men and 103 (66.5%)
of women. Patients’ baseline characteristics are summarized in
Table 1.
%DVHOLQHDEGRPLQDOREHVLW\DQGDGYDQFHGOLYHUVWLIIQHVV
Out of 250 successful measurements (7.6%), 19 patients were
GLDJQRVHGZLWKDQDGYDQFHGOLYHUVWLIIQHVV/60.3D&HQ­
WUDOREHVLW\DQGDGYDQFHGOLYHUVWLIIQHVVVKRZHGDVLJQL¿FDQWUHOD­
tionship in Chi-square test (P-value = 0.048) (Table 2). 
3UHGLFWLYH UROHRI YLUDO DQGKRVW IDFWRUV LQ DGYDQFHG OLYHU VWLIIQHVV
ORJLVWLFUHJUHVVLRQ
In univariate analysis, we examined the predictive values of
each variable that assumed to play a role in further liver stiffness
MHz) after at least 3 hours of fasting. According to the manufac­
turer’s guidelines, the M and XL probes were used for individuals
with a thoracic perimeter of less than or above 110 cm, respec­
tively. With the patient lying in the dorsal decubitus position with
maximal abduction of the right arm, the probe was placed on the
skin overlying the right lobe of the liver, through the intercostal
spaces. At least 10 measurements were done for each patient and
the median value was recorded. Values were considered valid if
the inter-quartile range (IQR) was less than 30% of the median
reading and the success rate was at least 60%. The median value
was calculated automatically and expressed in kilopascals (kPa).
Transient elastography was not performed in cases of any degree
of ascites; ferromagnetic tools in the body; pregnancy; or mor­
ELGREHVLW\%RG\0DVV,QGH[NJP2) as suggested by the 3UHGLFWLYHUROHRIYLUDODQGKRVWIDFWRUVLQ$/7PHDVXUHVORJLVWLFUH-
PDQXIDFWXUHU7KHFXWRIIIRUWKHDGYDQFHGOLYHU¿EURVLVZDVVHW gression) 
including: age, gender, ethnicity, BMI, abdominal obesity, hyper­
tension, viral load, alcohol drinking, opiate consumption and to­
bacco smoking. 
We found that waist circumference, BMI, viral load, alcohol
consumption, opiate consumption and hypertension had a P-value
less than 0.2 or biological plausibility. These variables were then
entered into a multivariate model (logistic regression test), except
for BMI (due to the interaction with waist circumference). In mul­
tivariate analysis, associations of central obesity (Adjusted
OR = 4.3, P-value = 0.034) and viral load (Adjusted OR =
5.02, P-value = 0.016) with advanced liver stiffness remained
VWDWLVWLFDOO\VLJQL¿FDQW7DEOH
as equal or greater than 8 KPa. In the univariate analysis, BMI, gender, age, viral load and opi­
ate consumption showed a P-value < 0.5. In multivariate analysis,
+%9'1$4XDQWL¿FDWLRQ viral load (P-value = 0.008), gender (P-value = 0.005) and age
HBV DNA was extracted from 200 mL of serum using the (PYDOXH UHPDLQHGVLJQL¿FDQW7DEOH
QIAampDNA Blood Mini Kit (QIAGEN, Valencia, CA,
86$ DQG TXDQWL¿HG LQ WKH /LJKW&\FOHU 5RFKH 'LDJQRVWLFV Discussion 
Mannheim, Germany) by the artus RealArtTMHBV LC PCR
(QIAGEN, Hilden, Germany) according to the manufacturer’s in­ 5HVXOWVRIWKHSUHVHQWVWXG\VKRZHGDVLJQL¿FDQWDVVRFLDWLRQEH­
structions. The linear range of this assay was 102 – 109 copies/mL. tween the waist circumference and advanced liver stiffness.
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Table 1. Baseline characteristics of chronic hepatitis B patients in Golestan Hepatitis B Cohort Study 
 Variables N (%) 
Age (years) 
< 45 

64 (21.1) 
240 (78.9)
 Ethnicity 
Turkmen 
Non-Turkmen 
190 (62.5) 
114 (37.5) 
BMI (kg/m2) 
Normal 
Obese/overweight 
80 (26.3) 
224 (73.7)
 HTN 
No 
Yes 
142 (46.7) 
162 (53.3) 
Waist circumference 
Normal 
Abnormal (central obesity) 
109 (35.9) 
195 (64.1) 
Log10 viral load (IU/mL) 
< 2000 

283 (93.1) 
21 (6.9) 
Table 2. $GYDQFHGOLYHU¿EURVLVDWIROORZXSLQ&+%SDWLHQWVUHJDUGVWRWKHFHQWUDOREHVLW\DWEDVHOLQH
< 8, N (%) 
Waist circumference 
Normal 
Central obesity 
89 (96.7) 
142 (90) 
Total 231 (92.4) 
Liver Stiffness Measurement (KPa) 
Total P-value 
1
3 (3.3) 92 (100) 
16 (10) 158 (100) 0.048 
19 (7.6) 250 (100) 
Table 3. Logistic regression model of factors related to the advanced liver stiffness in cases of chronic hepatitis B 
Variables 
Age (year)
 < 45 

Gender 
Male (reference) 
Female 
Ethnicity 
Turkmen (reference) 
Fars 
BMI (kg/m2) 
Normal (< 25) 
2YHUZHLJKW2EHVH
Waist circumference (cm) 
Normal (reference) 
Central obesity 
Hypertension 
No (reference) 
Yes 
Viral load 
< 2000 IU/L 
,8/
Alcohol 
No (reference) 
Yes 
Opiate 
No (reference) 
Yes 
Cigar 
No (reference) 
Yes 
Univariate Multivariate 
Crude OR 95% CI P Adjusted OR 95% CI P
0.8 0.27–2.3 0.67 - - ­ - - ­ - - ­
1.32 0.51–3.4 0.57 - - ­ - - ­ - - ­
1.25 0.45–3.23 0.65 - - ­ - - ­ - - ­
3.33 0.75–14.81 0.11 - - ­ - - ­ - - ­
3.34 0.95–11.8 0.06 4.3 1.08–16.6 0.03 
1.74 0.67–4.5 0.25 2.03 0.75–5.5 0.16 
3.6 1.06–12.06 0.04 5.02 1.36–18.62 0.016 
2.6 0.53–12.83 0.24 5.08 0.82–31.22 0.8 
0.44 0.6–3.42 0.44 0.41 0.04–3.97 0.45 
1.31 0.41–4.17 0.64 - - - - - - - - ­
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Table  4. Logistic regression model of factors related to the ALT serum level in cases of chronic hepatitis B 
Variables 
Age(year) 
< 45(reference) 

Gender 
Male (reference) 
Female 
Ethnicity 
Turkmen (reference) 
Fars 
BMI (kg/m2) 
Normal (< 25) 
2YHUZHLJKW2EHVH
Waist circumference (cm) 
Normal (reference) 
Central obesity 
Hypertension 
No (reference) 
Yes 
Viral load 
< 2000 IU/L 
,8/
Alcohol 
No (reference) 
Yes 
Opiate 
No (reference) 
Yes 
Cigar 
No (reference) 
Yes 
Univariate Multivariate 
&UXGH6WDQGDUGL]HGȕ 95% CI P $GMXVWHG6WDQGDUGL]HGȕ 95% CI P
-0.104 23.96–34.58 0.070 -0.114 -11.9– -0.35 0.042 
-0.131 25.72–41.17 0.023 -0.164 -12.03– -2.18 0.005 
-0.010 -5.5–4.6 0.86 - - ­ - - ­ - - ­
0.16 2.34–13.32 0.005 0.142 1.52–12.61 0.015 
0.033 -3.62–6.6 0.57 - - ­ - - ­ - - ­
-0.035 -6.44–3.37 0.54 - - ­ - - ­ - - ­
0.147 2.99–22.09 0.01 0.15 - - ­ 0.008 
0.001 -10.05–10.17 0.1 - - ­ - - ­ - - ­
-0.11 -16.12– -0.5 0.05 -0.082 -17.48– -0.7 0.16 
-0.009 -6.94–5.87 0.87 - - ­ - - ­ - - ­
In their cross-sectional cohort study on 94 chronic inactive HBV
FDUULHUVLQ6SDLQ0HQDHWDOUHSRUWHGDVLJQL¿FDQWDVVR­
FLDWLRQEHWZHHQFHQWUDOREHVLW\DQGDGYDQFHGOLYHU¿EURVLV+RZ­
ever, no relation was found between factors like age, sex, transam­
LQDVHV+%9'1$OHYHORUJHQRW\SHDQGWKHOLYHU¿EURVLVLQWKHLU
study.16 In China (2014), Wong, et al. followed 663 naïve CHB
SDWLHQWVIRUDERXWIRXU\HDUVDQGUHSRUWHGDVLJQL¿FDQWDVVRFLDWLRQ
between coincidental metabolic syndrome, central obesity and
ORZOHYHORIKLJKGHQVLW\OLSRSURWHLQFKROHVWHUROZLWKOLYHU¿EUR­
sis progression independent of viral load change and ALT level.17 
There are also other reports about the adverse effect of general
obesity (high BMI) on the liver-related morbidity and mortality
sectional study on 83 CHB patients in Brasil, suggesting a role for
alteration in the metabolic factors in liver disease progression of
HBV cases.23 
However, a cross-sectional study in Indonesia of 174 CHB pa­
tients (56% HBeAg negative) reported an association between
KLJKHU%0,DQGOLYHUVWHDWRVLVEXWQRDVVRFLDWLRQZLWK¿EURVLV24 
&RQVLGHULQJDOOWKHVHGDWDWRJHWKHUREHVLW\DQGVSHFL¿FDOO\FHQ­
tral obesity may play an important role in the progression of liver
diseases. 
$VLJQL¿FDQWDVVRFLDWLRQZDVIRXQGEHWZHHQWKHEDVHOLQHYLUDO
ORDGORJLQ&+%SDWLHQWVDQGDGYDQFHGOLYHU¿EURVLV/60
8 KPa) in a 4 years follow-up. To the best of our knowledge, due
to the lack of longitudinal and cohort studies, this association hascontributing to the non-alcoholic fatty liver, non-alcoholic steato­
hepatitis, cirrhosis and HCC.18–20 not been studied extensively. There is just one other cross-sectional
In a retrospective study on 136 eAg negative CHB in Taiwan study from China that found a correlation between steatosis and
WKHDXWKRUVUHSRUWHGPRUHDGYDQFHGOLYHU¿EURVLVVWDJHV the hepatitis B virus (HBV)–DNA levels.18 Future studies on the
and grades in those with higher BMI and viral load and observed current topic are therefore recommended. Our major limitation
a synergistic association of BMI and viral load on the progression was a small amount of CHB cases with possible or probable cir­
of liver disease.20 In another recent published paper from Turkey UKRVLV$OWKRXJKLWKDVEHHQSUHYLRXVO\VKRZHGWKDWOLYHU¿EURVLV
(2014), Demir, et al. reported a positive correlation between ad­ progression would be uncommon within 3 – 4 years of follow­
YDQFHG¿EURVLVZKLFKKDVEHHQVHHQLQDQGKLJKHU%0, up in inactive chronic HBeAg-negative hepatitis B patients with
AST and ALT level, as well as HBV DNA level in 456 CHB pa­ baseline HBV-DNA level < 20,000 IU/mL.25 Other limitations in­
tients.21 Furthermore, Chinese patients with chronic hepatitis B clude our lack of data on liver stiffness and other laboratory mark­
and BMI > 28 kg/m2 and abnormal levels of ALT had higher liver ers of liver disease at baseline. In addition, our results may not ap­
stiffness values in a study from Ding, et al.22 ply to other populations, particularly for patients who are HBeAg
Nau, et al. (2014) also observed an association between the pres­ positive or infected with other genotypes of HBV. 
ence of liver steatosis and higher BMI in a retrospective cross- Key strengths of our study include the comprehensive character-
Archives of Iranian Medicine, Volume 18, Number 9, September 2015 565 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
	
	
	
	
 
	
	
	
 
	
	
	
	
	
	
 
	
	
	
 
	
 
	
	
	
	
           
 
	
         
	
	
	
         
L]DWLRQRI+%9LQIHFWLRQDQGOLYHUGLVHDVH2XUVWXG\DOVREHQH¿W­
ed from a population-based setting and enrollment of participants
from a homogenous ethnic group who were all HBeAg negative
and infected by HBV genotype D.
In conclusions, in the present study, we observed an association
between central obesity and advanced liver stiffness in the context
of hepatitis B virus infection. Patients with HBV and coexisting
central obesity are recommended to reduce their weight, for pre­
vention of liver disease and other chronic disease.
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